INNsight Newsletter - May edition
Welcome to the May edition of INNsight Newsletter, where we share with you the latest news and insights from?IQVIA Global Market Insights.
This month's thought leadership includes:
KRAS Mutation: An Update on Key Selected Pipeline Developments and Clinical Trials for KRAS Targeting Therapies
Some of the deadliest cancers harbor mutations in the Kirsten rat sarcoma virus (KRAS) gene. The recent development of therapies that target and kill cancer cells with these mutations was heralded as a significant breakthrough.??This article provides an update on current treatment options for KRAS-driven tumors and outlines the latest development activities including ongoing clinical trials of key experimental drugs. Read more
领英推荐
Horizon Scanning: Universal Healthcare in South Africa
From 2009, the South African government has taken more proactive measures to lay the foundations for an eventual National Health Insurance (NHI) fund.??This article provides a review of the proposed National Health Insurance Fund, and presents an overview of its potential impact on key stakeholders, including healthcare professionals, medical scheme administrators and the pharmaceutical industry. Read more
MIDAS Early Bird: Sales Trends of 2023 and Implications for the Future
Overall, 2023 was a year marked by significant progress in terms of therapeutic innovation. However, 2023 was also a year in which challenges from the COVID-19 pandemic persisted: overall uptake of innovative launches remained well below pre-pandemic uptake in the major markets, and global volume of innovative prescription medicines failed yet again to recover to 2019 levels. This analysis examines major trends of last year and their implications for the future. Read more
To learn about IQVIA Global Market Insights' solutions and how we can support your business, follow this link.